CN1252057C - 用于治疗与paar有关的疾病的噻唑衍生物 - Google Patents

用于治疗与paar有关的疾病的噻唑衍生物 Download PDF

Info

Publication number
CN1252057C
CN1252057C CNB018223095A CN01822309A CN1252057C CN 1252057 C CN1252057 C CN 1252057C CN B018223095 A CNB018223095 A CN B018223095A CN 01822309 A CN01822309 A CN 01822309A CN 1252057 C CN1252057 C CN 1252057C
Authority
CN
China
Prior art keywords
methyl
trifluoromethyl
thiazole
title compound
phenoxy group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018223095A
Other languages
English (en)
Chinese (zh)
Other versions
CN1527822A (zh
Inventor
R·卡迪拉
R·L·M·戈斯米尼
M·H·拉姆伯特三世
M·L·西拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1527822A publication Critical patent/CN1527822A/zh
Application granted granted Critical
Publication of CN1252057C publication Critical patent/CN1252057C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018223095A 2000-12-20 2001-12-19 用于治疗与paar有关的疾病的噻唑衍生物 Expired - Fee Related CN1252057C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
GB0031107.6 2000-12-20

Publications (2)

Publication Number Publication Date
CN1527822A CN1527822A (zh) 2004-09-08
CN1252057C true CN1252057C (zh) 2006-04-19

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018223095A Expired - Fee Related CN1252057C (zh) 2000-12-20 2001-12-19 用于治疗与paar有关的疾病的噻唑衍生物

Country Status (27)

Country Link
EP (1) EP1343773B1 (https=)
JP (1) JP4209681B2 (https=)
KR (1) KR100815022B1 (https=)
CN (1) CN1252057C (https=)
AR (1) AR035522A1 (https=)
AT (1) ATE344253T1 (https=)
AU (1) AU2002246713B2 (https=)
BR (1) BR0116370A (https=)
CA (1) CA2432188A1 (https=)
CY (1) CY1105915T1 (https=)
CZ (1) CZ20031737A3 (https=)
DE (1) DE60124302T2 (https=)
DK (1) DK1343773T3 (https=)
ES (1) ES2274914T3 (https=)
GB (1) GB0031107D0 (https=)
HU (1) HUP0400837A3 (https=)
IL (2) IL156436A0 (https=)
MX (1) MXPA03005699A (https=)
MY (1) MY136685A (https=)
NO (1) NO20032801L (https=)
NZ (1) NZ526543A (https=)
PL (1) PL365797A1 (https=)
PT (1) PT1343773E (https=)
SI (1) SI1343773T1 (https=)
TW (1) TWI292759B (https=)
WO (1) WO2002062774A1 (https=)
ZA (1) ZA200304679B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU5884101A (en) 2000-05-26 2001-12-03 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
RU2005141516A (ru) 2003-06-06 2007-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные анилина
KR100796093B1 (ko) 2003-07-02 2008-01-21 에프. 호프만-라 로슈 아게 티아졸 고리로 치환된 인돌릴 유도체 및 ｐｐａｒ조절제로서 그의 용도
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
AU2005320387A1 (en) * 2004-12-31 2006-07-06 Seoul National University Industry Foundation Organoselenium containing compounds and their use
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
WO2006091047A1 (en) 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CN101595089A (zh) 2006-12-02 2009-12-02 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
JP5367584B2 (ja) * 2007-01-08 2013-12-11 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドチアゾール化合物及びこれを含有する医薬、化粧品及び健康食品組成物
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
JP2004518702A (ja) 2004-06-24
DE60124302T2 (de) 2007-05-03
DK1343773T3 (da) 2007-02-05
AU2002246713B2 (en) 2004-09-09
NO20032801L (no) 2003-08-04
DE60124302D1 (de) 2006-12-14
EP1343773A1 (en) 2003-09-17
KR20030072571A (ko) 2003-09-15
CY1105915T1 (el) 2011-04-06
ES2274914T3 (es) 2007-06-01
TWI292759B (en) 2008-01-21
HUP0400837A2 (hu) 2004-08-30
ZA200304679B (en) 2004-10-04
HUP0400837A3 (en) 2007-11-28
IL156436A0 (en) 2004-01-04
NO20032801D0 (no) 2003-06-19
WO2002062774A1 (en) 2002-08-15
EP1343773B1 (en) 2006-11-02
CA2432188A1 (en) 2002-08-15
ATE344253T1 (de) 2006-11-15
CN1527822A (zh) 2004-09-08
JP4209681B2 (ja) 2009-01-14
MXPA03005699A (es) 2003-10-06
HK1059925A1 (en) 2004-07-23
MY136685A (en) 2008-11-28
PT1343773E (pt) 2007-02-28
PL365797A1 (en) 2005-01-10
GB0031107D0 (en) 2001-01-31
SI1343773T1 (sl) 2007-04-30
IL156436A (en) 2008-06-05
BR0116370A (pt) 2003-12-09
KR100815022B1 (ko) 2008-03-18
AR035522A1 (es) 2004-06-02
CZ20031737A3 (cs) 2003-10-15
NZ526543A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
CN1252057C (zh) 用于治疗与paar有关的疾病的噻唑衍生物
CN1184215C (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
CN1164579C (zh) 噻唑和噁唑衍生物以及它们的药物应用
CN100349856C (zh) 丙酸衍生物及其作为hPPAR活化剂的用途
CN1228327C (zh) 羧酸衍生物和包含它们的药物
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1032751C (zh) 噻唑烷化合物，其制备及其治疗用途
CN1529698A (zh) 用于治疗心血管及有关疾病的噻唑或噁唑衍生物
CN1638768A (zh) 调节ppar活性的噻唑和噁唑衍生物
CN101048402A (zh) 咔唑衍生物、其溶剂合物或其药学上允许的盐
CN1568316A (zh) 过氧化物酶体增殖剂响应受体δ活化剂
CN1571766A (zh) 二羧酸衍生物、其制备和治疗应用
CN1290700A (zh) 苯基哌嗪衍生物
CN1058964C (zh) 支链氨基被取代的噻唑、其制备方法及含有它们的药物组合物
CN1886133A (zh) 吲哚化合物
CN1812977A (zh) 取代羧酸
CN1558905A (zh) 茚满乙酸衍生物及其作为药物、中间体的用途以及制备方法
CN1069728A (zh) 美拉德反应抑制剂
CN1678596A (zh) 作为PPARα和PPARγ激动剂的新型2－芳基噻唑化合物
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1040791A (zh) 镇痛羧酸酰胺衍生物
CN1753879A (zh) 作为用于治疗2型糖尿病和动脉硬化症的ppar调节剂的3－(2－苯基－噁唑－4－基甲氧基)环己基甲氧基乙酸衍生物和相关化合物
CN1681808A (zh) 作为ppar激动剂用于治疗糖尿病的n－取代－1h－吲哚－5－丙酸化合物
CN1074679A (zh) 含有醌基的噻唑烷化合物其制备及其治疗用途
CN101039936A (zh) 作为i－型纤溶酶原激活剂抑制剂(pai－1)调节剂用于治疗血栓形成和心血管疾病的唑基－萘基酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060419

Termination date: 20101219